[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647392":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":37,"locations":47,"responsibleParty":63,"collaborators":67,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":27,"enrollmentInfo":92,"targetDuration":27,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":108,"whyStopped":27,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional Chemoradiotherapy (CONV)","ACTIVE_COMPARATOR","Participants assigned to this arm will receive conventionally fractionated whole pelvic external beam radiotherapy (45 Gy in 25 fractions or equivalent institutional standard) using IMRT\u002FVMAT techniques, administered concurrently with weekly platinum-based chemotherapy, followed by image-guided adaptive brachytherapy according to institutional protocols.",[13,14],"Radiation: Conventional Chemoradiotherapy","Drug: Concurrent chemotherapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Hypofractionated Chemoradiotherapy (HYPO)","EXPERIMENTAL","Participants assigned to this arm will receive hypofractionated whole pelvic external beam radiotherapy (44 Gy in 20 fractions) using IMRT\u002FVMAT techniques, administered concurrently with weekly platinum-based chemotherapy, followed by image-guided adaptive brachytherapy according to institutional protocols.",[20,14],"Radiation: Hypofractionated Chemoradiotherapy",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"RADIATION","Hypofractionated Chemoradiotherapy","Whole pelvic external beam radiotherapy delivered using IMRT or VMAT techniques at a dose of 44 Gy in 20 fractions (2.2 Gy per fraction), administered once daily, five fractions per week. Treatment is given concurrently with weekly platinum-based chemotherapy and followed by image-guided adaptive brachytherapy according to institutional protocols.",[16],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Conventional Chemoradiotherapy","Whole pelvic external beam radiotherapy delivered using IMRT or VMAT techniques at a dose of 45 Gy in 25 fractions (1.8 Gy per fraction), administered once daily, five fractions per week. Treatment is given concurrently with weekly platinum-based chemotherapy and followed by image-guided adaptive brachytherapy according to institutional protocols.",[9],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"DRUG","Concurrent chemotherapy","Concurrent chemotherapy once a week Cisplatin-based concurrent chemotherapy administered intravenously at a dose of 40 mg\u002Fm² once weekly during external beam radiotherapy for 5 to 6 cycles.",[9,16],[38,43],{"name":39,"role":40,"phone":41,"phoneExt":27,"email":42},"Tissana Prasartseree, MD","CONTACT","66625246101","tissana.p@gmail.com",{"name":44,"role":40,"phone":45,"phoneExt":27,"email":46},"Pittaya Dankulchai, MD","66966233606","pittaya.dan@mahidol.ac.th",[48],{"facility":49,"status":27,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Siriraj Hospital","Bangkok Noi","Bangkok","10700","Thailand","TH",{"type":56,"coordinates":57},"Point",[58,59],100.47798,13.76266,{"lat":59,"lon":58},[62],{"name":39,"role":40,"phone":41,"phoneExt":27,"email":42},{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Tissana Prasartseree","Dr.",[68,70,72,73,75,78,80],{"name":69,"class":6},"Chiang Mai University",{"name":71,"class":6},"Prince of Songkla University",{"name":49,"class":6},{"name":74,"class":6},"Ratchaburi Hospital",{"name":76,"class":77},"Tha Chalom Hospital","UNKNOWN",{"name":79,"class":6},"Chulabhorn Hospital",{"name":81,"class":77},"Lopburi Hospital","100647392","phase-3-hypofractionated-chemoradiotherapy-for-cervical-cancer-100647392",false,"NCT07709650","Hypofractionated Chemoradiotherapy for Cervical Cancer","HYPOfractionated Whole Pelvic Concurrent Chemoradiotherapy in Cervical Cancer (HYPOCx Trial): A Phase III Randomized Controlled Trial","HYPOCx","Inclusion Criteria:\n\n1. Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including imaged-guided BT\n2. Positive biopsy showing squamous-cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma of the uterine cervix\n3. Locally advanced staging according to FIGO 2018 and TNM guidelines (Stage IA1-IVA)\n4. MRI of the pelvis at diagnosis is performed\n5. MRI, CT, or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed\n6. MRI with the applicator in place at the time of (first) BT will be performed\n7. GFR ≥ 50 mL\u002Fmin\n8. Patient informed consent\n\nExclusion Criteria:\n\n1. Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin\n2. Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix\n3. Metastatic disease beyond intervertebral disc L2\u002F3 level\n4. Previous pelvic or abdominal radiotherapy\n5. Previous total or subtotal hysterectomy\n6. Combination of preoperative radiotherapy with surgery\n7. Patients receiving BT only\n8. Patients receiving EBRT only\n9. Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg\u002Fm2).\n10. Contra-indications to MRI\n11. Contra-indications to BT","FEMALE","18 Years",{"count":93,"type":94},250,"ESTIMATED","INTERVENTIONAL",[97],"PHASE3","Cervical cancer remains a major health problem in Thailand and other lowand middle-income countries. The current standard treatment for locally advanced cervical cancer consists of conventionally fractionated external beam radiotherapy delivered over 5-7 weeks with concurrent chemotherapy, followed by brachytherapy. This prolonged treatment schedule requires frequent hospital visits and may limit access to care. Hypofractionated radiotherapy delivers a higher dose of radiation per treatment session while maintaining a comparable total radiation dose, thereby reducing the overall treatment duration. Preliminary studies suggest that hypofractionated chemoradiotherapy using modern radiotherapy techniques may provide similar disease control and acceptable toxicity compared with conventional treatment, while improving treatment convenience and reducing healthcare burden. This multicenter phase III randomized controlled trial aims to compare hypofractionated whole pelvic concurrent chemoradiotherapy with conventional chemoradiotherapy in patients with early-stage node-positive and locally advanced cervical cancer. The study will evaluate nodal control and overall survival, as well as tumor response, treatment-related toxicities, quality of life, and cost-effectiveness.",[100],"Cervival Cancer",[102,103,104,105,106,107],"Cervical Cancer","Hypofractionated Radiotherapy","Conventional Radiotherapy","Whole Pelvic Radiotherapy","Chemoradiotherapy","Brachytherapy","NOT_YET_RECRUITING","2026-07-12",{"date":111,"type":112},"2026-07-16","ACTUAL",{"date":114,"type":94},"2026-08",{"date":116,"type":94},"2033-06",{"name":5,"class":6},1]